Description
Lamivudine & Zidovudine tablets
Lamivudine & Zidovudine Tablets (150 mg / 300 mg)
Healthy Inc is a specialized global supplier and exporter of advanced infectious disease, immunology, and public health therapeutics. We provide ultra-high-purity, kinetically stable Lamivudine and Zidovudine FDC Tablets, manufactured in WHO–GMP certified, high-precision antiretroviral manufacturing facilities. This “Nucleoside Reverse Transcriptase Inhibitor (NRTI) Combination” is a massive-volume strategic export to National AIDS Control Organizations, global health NGOs, and international B2B distributors, serving as the globally preferred backbone for the long-term management of HIV-1 infection.
Product Overview
This formulation operates as a “Genetic Chain Terminator.” It ensures patient safety by blocking the virus’s ability to convert its RNA into DNA, physically preventing it from integrating into the host’s immune cells.
Mechanism 1 (Nucleoside Mimicry): Both Lamivudine and Zidovudine are physically engineered to resemble natural deoxynucleotides. The HIV enzyme, Reverse Transcriptase, chemically mistakes these drugs for actual DNA building blocks.
Mechanism 2 (Chain Termination): Once the enzyme incorporates the drug into the growing viral DNA strand, it physically lacks the chemical “hook” (3′-OH group) needed to attach the next block. This chemically and physically Terminates the DNA Chain.
Mechanism 3 (Dual-Synergy): By using two different NRTIs, the treatment physically increases the barrier to resistance, chemically ensuring a more robust suppression of the viral load than monotherapy.
Product Composition & Strength
We supply this product in the internationally standardized Fixed-Dose Combination (FDC) required for therapeutic compliance.
| Active Ingredient | Strength (per Tablet) | Primary Clinical Function |
| Lamivudine (3TC) IP/BP/USP | 150 mg | The Chain Terminator: High potency, low toxicity. |
| Zidovudine (AZT) IP/BP/USP | 300 mg | The Foundation: Proven efficacy in preventing replication. |
| Excipients | Pharma Grade | The Matrix: Ensures stability of the sensitive FDC. |
Technical & Logistics Specifications
HS Code: 3004.90.99 (Medicaments acting on infectious diseases / Antivirals)
CAS Numbers: 134678-17-4 (Lamivudine) / 30516-87-1 (Zidovudine)
Dosage Form: Oral Tablet (Film-Coated)
Packaging: 10 or 60 Tablets per Bottle/Blister. We utilize high-density induction-sealed bottles or Alu-Alu blisters to physically prevent moisture ingress, ensuring 36-month stability in Zone IVb tropical climates.
Manufacturing Authority & Compliance
ARV Specialized Line: HIV medications require the highest level of cross-contamination control. Our manufacturing process utilizes Dedicated High-Containment Facilities, physically ensuring that no other drug particles chemically interfere with the ARV matrix.
Bioequivalence Verification: We utilize Comparative Dissolution Profiling, physically ensuring our FDC is chemically bioequivalent to the innovator brand—a critical factor for NGO and Government tender qualification.
Photo-Stability: Zidovudine is physically sensitive to light. We utilize Opaque Film Coating and light-resistant packaging, chemically ensuring the drug remains potent until the point of ingestion.
Primary Indications
HIV/AIDS Management: Part of a multi-drug regimen for the treatment of HIV-1 Infection.
Occupational Safety: Used in Post-Exposure Prophylaxis (PEP) following potential needle-stick or sexual exposure.
Maternal Health: Prevention of Mother-to-Child Transmission (PMTCT) during pregnancy and delivery.
Usage Instructions
Dosage: Typically one tablet twice daily (every 12 hours).
Administration: Swallow the tablet physically whole with or without food.
Consistency: Adherence is physically critical. Missing doses chemically allows the virus to replicate and physically increases the risk of Drug Resistance.
Monitoring: Patients must physically undergo regular CD4 Count and Viral Load Testing to chemically assess the treatment’s success.
Safety Warning: For Professional Use Only. Hematologic Note: Zidovudine may physically cause Anemia or Neutropenia; monitor blood counts chemically. Lactic Acidosis: Rare but severe physical risk of lactic acidosis and hepatic steatosis. Contraindication: Do not use in patients with severe anemia, very low neutrophil counts, or known hypersensitivity to Lamivudine or Zidovudine.
Global Export & Contract Manufacturing
Healthy Inc is a premier Antiretroviral and Public Health Pharmaceutical Exporter in India. As a verified Medicine Supplier in Mumbai, we offer flexible Third Party Manufacturing (Contract Manufacturing) for high-volume ARV FDCs. Whether you are a National Ministry of Health in Africa or a B2B Pharma Marketplace partner in the CIS or SE Asia, we ensure secure, WHO-GMP compliant delivery.
Commercial Inquiries:
WhatsApp/Call: +91 7710003340
Email: info@healthyinc.co.in
